News

The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need - FDA approval paves the way for the ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...
General, Winnie Byanyima, has called for a drastic and transparent reduction in the cost of lenacapavir, a twice-yearly ...
The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...